Evidence summary
12 relevant scholarly record(s) and 4 relevant trial record(s) were collected for the resolved component identities.
Research
Compound Research
Review source-grounded research summaries, evidence classifications, limitations, and registered trials.
Compound research
One canonical approved research record powers this product page, the Compound Directory, the Research Library, and related article pages.
Open compound profilePreclinical evidence
Relevant preclinical records were identified for one or more resolved components. Review each source-specific model, outcome, and limitation before approval.
Human evidence
Relevant human literature and/or registered trial records were identified for one or more resolved components. Registration alone does not establish results.
Evidence limitations
Evidence is organized by resolved component. Automated discovery may still miss records or encounter similarly named entities. Product-specific stability, purity, storage duration, shelf life, and lot results require verified manufacturer, laboratory, or ForgeOS COA records.
Registered clinical trials
All trialsNCT01280344 · COMPLETED
Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function
Post-operative administration of ipamorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial small and/or large bowel resection.
Registry record
NCT00672074 · COMPLETED
Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus
The purpose of this study is to determine if ipamorelin is safe and effective in the management of post-operative ileus.
Registry record
NCT03375788 · COMPLETED
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
Nonalcoholic fatty liver disease (NAFLD) is common in individuals with obesity and is a significant threat to public health, because it can lead to impaired liver function and liver failure. Growth hormone is a hormone produced in the pituitary gland that helps regulate metabolism and growth. Individuals with obesity, on average, secrete less growth hormone than individuals without obesity. There are data to suggest that growth hormone may help to reduce the amount of fat in the liver, and may also reduce inflammation in the liver, both of which would be helpful to individuals with NAFLD. The purpose of this study is to investigate whether treatment with a drug called tesamorelin, which is a growth hormone releasing hormone analogue, will decrease liver fat and improve liver inflammation and scarring in obese individuals with NAFLD.
Registry record
NCT07481734 · RECRUITING
Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)
This randomized, double-blind, placebo-controlled Phase II study evaluates whether daily subcutaneous tesamorelin (a growth hormone-releasing hormone analog) reduces liver fat in adults with fatty liver disease. Participants receive tesamorelin or matching placebo for 52 weeks, with standardized lifestyle counseling in both groups. Liver fat is quantified by MRI-proton density fat fraction (MRI-PDFF). Key safety monitoring includes glucose metrics and IGF-1.
Registry record
Educational summaries describe published research cautiously and do not make diagnostic, treatment, dosing, cure, or human-use claims. Human, animal, in-vitro, computational, and review evidence are identified separately. Registered trials are not the same as published results. Last reviewed: Not recorded.
